THE VALIDITY of the double isotopic tracer ratio (DITR) method for measuring fractional zinc absorption (FZA) has recently been questioned (8) . This method, first proposed by Friel et al. (3) for measuring FZA, is a modification of the DITR method for determining the fractional absorption of calcium (2, 10, 11) from the ratio of oral to intravenous stable isotopic tracers in a 24-h pooled collection of urine after tracer administration. Because the kinetics of zinc absorption into plasma are slower than those of calcium, Friel et al. suggested that DITR should be applied to either a 72-or 96-h pooled urine collection. The same group further suggested that accurate estimates of FZA could more easily be obtained by applying DITR to any spot sample collected after the time at which the slopes of the log transforms of both the oral and intravenous stable isotopic tracers in plasma became equal. The time of this occurrence was ϳ40 h after simultaneous tracer administration in their study.
The DITR method for determining FZA has recently been compared with the fecal monitoring method (8) , a commonly used technique for estimation of FZA. The fecal monitoring method, employing a single oral tracer with measurement of the tracer in each fecal sample, can provide an accurate estimate of FZA if the kinetics of tracer absorption can be separated from the kinetics of secretion of absorbed oral tracer, a problem not yet completely solved (9) . Friel et al. (3) found "good agreement" between the two methods, but Rautscher and Fairweather-Tait (8) concluded that DITR does "not reliably predict" FZA. On the basis of a number of experimental and simulation considerations, we believe that the fecal monitoring method is an inappropriate reference for assessing DITR (5, 9) . In addition, we believe that the latter method does provide a valid estimate of FZA (9) . However, we understand that a point against DITR as a validated measure of FZA is the lack of a theoretical analysis of its domain of validity.
In this paper, we consider six DITR techniques for estimation of FZA employing the simultaneous administration of two tracers, an oral and an intravenous tracer. In a theoretical environment, i.e., with errorfree and continuous-time tracer data, two of them are exact and will thus be used and referred to as "reference methods" (see REFERENCE METHODS TO CALCULATE FZA). The other four methods will be referred to as "approximate methods," because they provide, even in a theoretical environment, approximate estimates of FZA (see FZA BY APPROXIMATE METHODS). However, these approximate methods are clinically appealing, given their simplicity of implementation. In DOMAIN OF VALID-ITY OF APPROXIMATE METHODS, we investigate the accuracy of these approximate methods against the two refer-ence methods in a theoretical context. In particular, we show mathematically that the specific characteristics of zinc kinetics ensure accuracy of all the approximate methods.
REFERENCE METHODS TO CALCULATE FZA
We describe here two methods that, in a theoretical environment (i.e., error-free and continuous-time data), allow the measurement of FZA without error from data after the simultaneous administration of two tracers, an oral tracer and an intravenous tracer. Both of these methods assume that oral zinc behaves identically to the intravenous zinc once in the systemic circulation, that tracer kinetics are linear, and that all of the oral zinc absorbed from the gastrointestinal tract reaches the plasma.
Compartmental Modeling
Let us assume that the zinc metabolism in humans is described by the compartmental model shown in Fig. 1 (6) . In a given individual, FZA can be obtained by making use of the rate constants of the kinetic model by
with obvious meaning of notation (1) . It is worth noting that the practical use of Eq. 1 would require the identification of the model of Fig. 1 from tracer data. In particular, the model should be fitted against frequently sampled plasma, urine, and fecal concentrations of orally and intravenously administered stable isotopic tracers of zinc, 67 Zn-tr and 70 Zntr, highly enriched in 67 Zn and 70 Zn, respectively. This was the procedure used in Ref. 6 . It is also important to note that, because tracer concentration data are unavoidably affected by error, the FZA value obtainable by Eq. 1 is always uncertain (even assuming an errorfree model structure). This uncertainty reflects that of the parameters obtained from model fitting. However, because the aim of this paper is to evaluate the theoretical foundation of the DITR method, we will consider an error-free context, and we will not take into account precision issues.
Deconvolution
The theoretical rationale of this method is given in APPENDIX A, where we also make clear the improper labeling of this method as "deconvolution." In fact, there is no need for any deconvolution procedure to implement this method, which calculates FZA as the ratio of the areas under the curve (AUCs) of the oral and intravenous tracers, e.g., 67 Zn-tr and 70 Zn-tr
where, in general, 67 z i (t) denotes the concentration (e.g., measured in mg/ml) in pool i (1 is plasma; see Zn-tr at time 0. Even if practical aspects are outside the theoretical focus of the present paper, it is worth noting that the implementation of Eq. 2 would require frequent and prolonged sampling of intravenous and oral tracer concentration in plasma and some data extrapolation from the last measurement to time infinity. Moreover, because of data noise and interpolation/extrapolation errors, the FZA estimate provided by Eq. 2 would be uncertain.
Remark 1. Throughout the paper, we will consider, for sake of simplicity, responses to unit oral and intravenous tracer doses. Obviously, considering nonunit and different intravenous and oral doses is possible by considering in the formulas the proper scale factors.
The implementation of either of the two methods presented in this section requires a large amount of data. This motivated the development and usage of simpler, albeit approximate, techniques for FZA estimation. These are described in FZA BY APPROXIMATE METH-ODS. The same approximate methods will be assessed in DOMAIN OF VALIDITY OF APPROXIMATE METHODS against the reference methods.
FZA BY APPROXIMATE METHODS
In the previous section, we described two methods that, in a theoretical environment, allow the exact determination of FZA. There are at least four methods, numbered 1-4 below, that provide approximate measures of FZA. These approximate estimates will be denoted hereafter by the symbol FZA. Methods 
Method 1
The first approximate method provides an estimate of FZA as a ratio of AUCs of functions fitted to plasma data between the beginning of the experiment and t 
where t is a time greater than a certain threshold, t*. For zinc, this threshold is typically 2-3 days.
Method 2
The second approximate method provides an estimate of FZA by utilizing the concentration of each tracer in a total cumulative urine collection from time 0 to t
where t is a time greater than t*.
Method 3
The third approximate method provides FZA from a single plasma sample as
where t is a time greater than the threshold time t*.
Method 4
The fourth approximate method requires the knowledge of the concentration of the two tracers in a single urine specimen, from which FZA is estimated as
where t 2 and t 1 represent the beginning and end of the urine sample collection interval, with Zn-tr concentration in a complete, cumulative urine sample over several days is required. Simpler still is method 3, in which measurement of 67 Zn-tr and 70 Zn-tr concentration in a single plasma sample obtained a few days after tracer administration is all that is required. Perhaps the simplest of all is method 4, which only requires a single measurement of 67 Zn-tr and 70 Zn-tr concentration in a single spot urine specimen obtained a few days after tracer administration.
A formal proof of the reliability of these four approximate approaches for FZA estimation is not available in the literature. Such a proof will be developed in the following section by exploiting some specific characteristics of zinc kinetics, and, given its theoretical nature, it is obtained in a noise-free environment; i.e., we are concerned only with the accuracy of the four approximate methods and not with their uncertainty due to data noise.
DOMAIN OF VALIDITY OF APPROXIMATE METHODS

Method 1
Consider the kinetic model of Fig. 1 Zn-tr reflects the first-pass kinetics of movement through and absorption from the gastrointestinal tract. However, 67 Zn-tr that is absorbed into plasma equilibrates with the extraplasma zinc pools and routes of renal and gastrointestinal loss in the same manner as 70 Zn-tr administered intravenously. Consequently, at the time that the first-pass absorption process is complete or nearly complete (when all or nearly all of the unabsorbed oral tracer has passed out of the gut compartment), the plasma concentration time course of the oral tracer begins to assume the same shape as that of the intravenously administered tracer. In particular, because tracer kinetics can be assumed to be linear, for times t greater than a certain threshold t*, both 70 z 1 (t) and 67 z 1 (t) can be approximated by a sum of the same number k (k Ͻ 5) of decaying exponentials with the same eigenvalues
For instance, with the parameters of Fig. 1 , for times greater than 2-3 days, the decay of the both the oral and intravenous tracers in plasma is well described by the last three modes of the system, with eigenvalues ␣ j equal to 0.854, 0.186, and 0.0017 day Ϫ1 (corresponding to half-lives of 0.81, 3.73, and 408 days, respectively). The larger the value of t, the more the approximations of Eqs. 7 and 8 improve (because the modes corresponding to the absorption process in 67 Zn-tr completely vanish only at infinity, the equal sign only holds asymptotically).
Remark 2. Relationships between the parameters of the exponentials and the rate constants k ij in Fig. 1 could be found by analytically solving the system of ordinary differential equations describing the kinetics, e.g., by software such as Maple or Matlab, which handle symbolic calculations. Now, let us define (t) as the function that makes the following equation hold 67 z 1 ͑t͒ ϭ ͑t͒ 
The fact that, for times t greater than t*, 70 z 1 (t) and 67 z 1 (t) tend to assume the same shape means that in Eq. 9 the function (t) tends, as time increases, toward a constant value . Therefore, for any t Ͼ t*, one could write 67 z 1 ͑t͒ Х 70 z 1 ͑t͒
A grasp of Eq. 10 is offered by Fig. 2C , where a scale factor between the oral and the intravenous tracer decay can be seen in their log transforms, which are, roughly speaking, "parallel." Now, let us consider Eq. 2, from which true FZA can be obtained as 
where t is a generic time greater than t*. By integrating 67 z 1 (t) and 70 z 1 (t) from t to infinity and exploiting Eq. 10, we can write
Now, consider the third term of Eq. 11. Whereas the integrals from 0 to t increase with increasing t, those from t to ϩϱ decrease with increasing t . However, from Eq. 12, it follows that, for t Ͼ t*, the ratio
is approximately constant and equal to . Given that FZA is the ratio of two real numbers, the fact that the ratio ͐ t ϩ ϱ 67 
(see Eq. 2), it follows not only that for any t greater than t* Eq. 3 provides an approximate estimate of FZA but also that such an estimate approaches the true value of FZA when t is "very large." Remark 3. Method 1 does not require additional hypotheses with respect to the reference deconvolution method from which it is derived. In fact, the proof reported above simply exploits the principle of indistinguishability of the oral and intravenous tracers and the linearity of their kinetics.
Method 2
Let us consider (Fig. 1) 
which gives a measure of FZA according to methods 1 and 2, is an underestimate of true FZA. Remark 4. Method 2 is based on the same assumptions of the reference deconvolution method and on only one additional structure hypothesis, i.e., that the urine pool receives material only from the plasma compartment. In fact, it is this last hypothesis that leads to Eqs. 16 and 17 and thus to Eq. 18; no other structural hypotheses are required. Therefore, method 2 is, in theory, compatible with many kinetic structures other than that of Fig. 1 .
Methods 3 and 4
These two methods can be discussed together. In fact, for any pair of times (t 2 , t 1 ), with t 2 Ͼ t 1 Ͼ t* and t* defined as the time after which both 70 z 1 (t) and 67 z 1 (t) exhibit a multiexponential decay with the same eigenvalues (parallel behavior on semilog plot; see Fig.  2, B and C In particular, for any set of kinetic parameters, methods 3 and 4 always overestimate the true FZA. It is thus important to assess under which conditions, i.e., kinetic properties, the overestimation made by these two methods is negligible. If the amounts of 67 Zn-tr and 70 Zn-tr were administered simultaneously into the plasma (equal doses), the concentrations of 67 Zn-tr and 70 Zn-tr in the plasma would be equal at any time. Instead, the 67 Zn-tr is given orally and the plasma concentration of 67 Zn-tr is always lower than that of 70 Zn-tr. However, as discussed previously, at the time that the first-pass absorption process is complete or nearly complete, the plasma concentration time course of the oral tracer begins to assume the same shape as that of the intravenously administered tracer (see Fig. 2 ). This happens because the zinc system is generating, outside of the absorption process, eigenvalues that are slower than the slowest eigenvalue generated by the absorption process itself, so that the extraplasma distribution and the absorption processes are "completely separable." In more formal terms, for any time t Ͼ t*, one can think of the plasma kinetics of the orally administered tracer, 67 Zn-tr, as being the result of an "intravenous injection" of an apparent tracer dose D, delayed by an interval, t d , with respect to the intravenously injected tracer 70 Zn-tr
If the administered doses of the intravenous and oral tracers are unitary, the apparent dose D coincides with the fraction of the orally administered tracer that is absorbed into the plasma. Therefore
In practice, Eq. 30 is not used (see remark 5 below), and the following approximation is made
which yields the estimate FZA shown in method 3
The application of Eq. 32 instead of Eq. 30 will lead to an overestimation of FZA, because 70 z 1 ͑t͒ will always be less than 70 z 1 ͑t Ϫ t d ). The degree of FZA overestimation by Eq. 32 relative to Eq. 30 can be found by employing the following rationale.
For any t greater than t*, in light of Eq. 23, Eq. 32 provides virtually the same value. To find what this value is, let us choose a very high value of t, say t Ͼ t s , where t s is the time after which only the slowest exponential, with eigenvalue hereafter indicated by ␣ s , is still active (e.g., with the parameters of Fig. 1 , ␣ s ϭ 0.0017 day Ϫ1 ). By employing Eq. 8, it can be seen that under these conditions
For the reference parameters of Fig. 1 , t d turns out to be ϳ0.20 days, and ␣ s is ϳ0.0017 day
Ϫ1
. According to Eq. 34, this leads to an overestimate of FZA by ϳ0.03%. This overestimation perfectly matches that determined by numerical simulation, depicted in Fig. 3B .
Remark 5. It is worth pointing out that, from Fig. 3 , one cannot infer the average amount of error one could introduce in estimating FZA by the DITR method in practice. The purpose of Fig. 3 is simply to illustrate graphically the theoretical results on the approximate methods, e.g., asymptotic convergence to the reference value of methods 1 and 2, and existence of a bias in methods 3 and 4. Figure 3 was obtained by using the parameters shown in Fig. 1 , but the same qualitative conclusion would have been obtained for any other set of zinc kinetic parameters (see also Ref. 9 and remark 6) . A possible way to quantitatively assess the average bias of the approximate methods would be to resort to stochastic simulation, but this is beyond the scope of this paper.
Remark 6. From Eq. 34, it can be speculated that method 3 (and thus method 4 as well), albeit approximate, is quite robust. Even with values of t d and ␣ s quite different from those linked to the reference parameters of Fig. 1 , the asymptotic error of method 3 will likely be, in practice, small and less than that due to biological variability and the measurement errors associated with the determination of the plasma tracer concentrations. For instance, if the slowest eigenvalue ␣ s (linked to the exchange of zinc tracer with the slowly equilibrating pools) were 100 times greater than that obtained for the parameters of Fig. 1 (i. e., ␣ s ϭ 100 ϫ 0.0017 day Ϫ1 , corresponding to a half-life of 4.08 days) the overestimate of FZA would still be less than 3.5%. This explains why method 3 (and method 4) can be safely applied to estimate FZA in practice, even if we have shown that, in theory, they do not tend toward the correct value of FZA as time increases.
Remark 7. If the values of both t d and ␣ s were available, the formula (34) could be used to exactly correct by the proper scale factor the FZA estimate found by method 3 when a very large value t, larger than t s , is used.
Remark 8. Equation 34
can be also used, on a pseudoempirical basis, to predict the estimation error when method 3 is used at times much earlier than t s . For instance, by interpolating with a straight line the log transform of two plasma samples, e.g., for intravenous response on days 3 and 4 (solid line in Fig. 2, B and C) , one finds a value of 0.162 day Ϫ1 . If this value is plugged into Eq. 34 in place of the true ␣ s , the overestimate of FZA predicted would be ϳ3.3%. This FZA overestimation closely matches that exactly determined by numerical simulation (see Fig. 3 3) . In light of Eq. 34, we can state that its accuracy depends on the product ␣ s t d . Therefore, the smaller the slowest eigenvalue of the system is and/or the faster the absorption process is, the higher the potential accuracy is of method 3. Method 4 coincides with method 3 if the additional assumption, that the urine pool receives material only from the plasma compartment, is verified (this is the same hypothesis behind method 2; see remark 4).
CONCLUSIONS
Empirical approaches based on the plasma or urine measurements of the ratio of orally to intravenously administered zinc tracers, termed the DITR method, have been proposed in the literature to determine FZA. These approaches can have a significant clinical relevance in nutritional studies, because they allow the human and economic costs of such studies to be significantly reduced. However, the reliability of this technique has been questioned on empirical grounds, and a mathematical analysis of its domain of validity has been lacking.
In this paper, it has been shown in an error-free context that four simple-to-implement approximate approaches employing DITR provide estimates of FZA close to those obtainable by two reference methods. The basic assumptions behind these methods are the linearity of tracer kinetics, the physiological indistinguishability of the oral and intravenous tracers, the existence of a remote pool(s) slowly equilibrating with plasma (i.e., the slowest eigenvalue generated by the extraplasma zinc pools is smaller than the smallest of the eigenvalues that regulate the absorption process), and the existence of a single, unidirectional flux into the urine pool originating from plasma (for methods 2 and 4 only). All of the approximate methods that we presented require the investigator to acquire data at or until the time at which the intravenous and oral tracer concentration responses in plasma begin to exhibit the same multiexponential clearance. Methods 1 and 2 asymptotically tend toward the true fractional absorption value as time elapsed after tracer administration increases. In contrast, methods 3 and 4 are biased, and their potential accuracy depends on the speed of the absorption process relative to the slowest mode generated by the extraplasma zinc pools. In practice, as discussed at the end of DOMAIN OF VALIDITY OF APPROXI-MATE METHODS, typical zinc kinetics ensure that the (overestimation) error associated with methods 3 and 4 is small, irrespective of sex, age, and dietary intake (see also Ref. 9 for simulations of large changes in the model parameter values of Fig. 1 ).
In conclusion, this paper demonstrates that the DITR method can provide a reliable measure of FZA. A single sample of urine or plasma after an appropriate time after oral and intravenous tracer administration can yield estimates of FZA that are only slightly different from the value obtained by the reference methods. In particular, from the theoretical analysis performed in this paper, it could be argued that the estimation of FZA by tracer ratio in a spot urine spec-imen with the use of method 4 could be the method of choice in practice when data acquisition for compartmental modeling cannot be performed. In fact, in light of the analysis of DOMAIN OF VALIDITY OF APPROXIMATE METHODS, it follows that the theoretical error generated by method 4 will be small. Moreover, method 4 is simple to implement and requires limited subject compliance.
Finally, we would like to stress that the aim of this paper was to theoretically assess the accuracy of the DITR method in an error-free context. When any of the DITR methods is applied in practice, one must take into account that the FZA estimate will be unavoidably uncertain because of data noise and also because of sparseness of sampling for the methods of Eqs. 1-3. A possible way to evaluate the precision of DITR methods in practice would be to resort to stochastic simulation, and this issue certainly deserves further investigation.
